Nöroendokrin diferansiasyon gösteren prostat adenokarsinomu. Prostate adenocarcinoma with neuroendocrine differentiation

Year 2018, , 157 - 160, 14.05.2018

Betül Demirciler Yavaş

https://doi.org/10.5505/ptd.2017.93824

Abstract

Nöroendokrin diferansiasyon gösteren prostat tümörleri oldukça nadir
görülür. Nöroendokrin komponent fazla oranda bulunduğunda, kanda PSA değerleri
daha az oranda yükselir. Prostat asiner adenokarsinom alanlarından farklı
olarak, nöroendokrin diferansiasyon gösteren tümör alanlarında androjen
reseptörleri bulunmadığı için hormonal tedavi başarısı daha düşüktür. Lokal
yayılım ve metastaz sık görülür. Mikroskopik incelemesinde nöroendokrin
komponentin varlığının bildirilmesi, hastanın tedavisini yönlendirmede ve
prognozunu tahmin etmede oldukça önemlidir.

Türkçe Kısa Başlık: Nöroendokrin diferansiasyonlu prostat adenokarsinomu

Keywords

Nöroendokrin diferansiasyon, adenokarsinom, prostat

Prostate adenocarcinoma with neuroendocrine differentiation.

Abstract

Prostate tumors with neuroendocrine differentiation are very rare. The more neuroendocrine component, the less the increase in PSA level. Because no androgen receptors are detected in tumor areas with neuroendocrine differentiation, as opposed to prostate aciner carcinoma places, hormonal therapy efficacy is insufficient. Local invasion and metastasis are common. In microscopical evaluation, the presence and nature of neuroendocrine component of tumor is very important to guide treatment protocol and to predict prognosis.

İngilizce Kısa Başlık: Prostate adenocarcinoma with neuroendocrine differentiation

Keywords

Neuroendocrine differentiation, adenocarcinoma, prostate

References

• 1. Parimi V, Goyal R, Poropatich K, Yang XJ. Neuroendocrine differentiation of prostate cancer: a review. Am J Clin Exp Urol 2014;2:273-285.
• 2. Ergin G, Kaya D, Yalçın E, Deveci MS, Özgök İY. Küçük hücreli prostat kanseri: nadir görülen bir olgu sunumu. Bulletin of Urooncology 2015;14:238-240.
• 3. Karada S, Kalfazade N, Aras B, Gürbüz N. Nadir görülen bir prostat tümörü: prostat küçük hücreli nöroendokrin karsinom. Medical Journal of Bakırköy 2009;5:170-172.
• 4. Hoof P, Nguyen GT, Paulson S, Syed A, Mora A. Neuroendocrine carcinoma of the prostate gland. Proc (Bayl Univ Med Cent) 2016;29:68-69.
• 5. Aparicio A, Tzelepi V. Neuroendocrine (small-cell) carcinomas: why they teach us essential lessons about prostate cancer. Oncology (Williston Park) 2014;28:831-838.
• 6. Priemer DS, Montironi R, Wang L, Williamson SR, Lopez-Beltran A, Cheng L. Neuroendocrine tumors of the prostate: emerging insights from molecular data and updates to the 2016 world health organization classification. Endocr Pathol 2016;27:123-135.
• 7. Li Q, Zhang CS, Zhang Y. Molecular aspects of prostate cancer with neuroendocrine differentiation. Chin J Cancer Res 2016;28:122-129.
• 8. Sagnak L, Topaloğlu H, Ozok U, Ersoy H. Prognostic significance of neuroendocrine differentiation in prostate adenocarcinoma. Clin Genitourin Cancer 2011;9:73-80.
• 9. Labrecque MP, Takhar MK, Nason R. et al. The retinoblastoma protein regulates hypoxia-inducible genetic programs, tumor cell invasiveness and neuroendocrine differentiation in prostate cancer cells. Oncotarget 2016;7: 24284.